Publications by authors named "Cheng-Pei Zhu"
Article Synopsis
- PD-1 inhibitors, alongside lenvatinib and transarterial chemoembolization (TACE), may offer improved outcomes for patients with unresectable hepatocellular carcinoma (uHCC) compared to standard lenvatinib and TACE treatment.
- A study of 65 patients found that those receiving the combination therapy had a significantly longer overall survival time of 26.8 months versus 14.0 months for the standard treatment group.
- The research utilized various assessment criteria to evaluate both efficacy and safety, highlighting the advantages of combining PD-1 inhibitors with other treatments for better patient prognosis.
Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
World J Gastroenterol
May 2016
Combined hepatocellular cholangiocarcinoma (CHC) accounts for 0.4%-14.2% of primary liver cancer cases and possesses pathological features of both hepatocellular carcinoma and cholangiocarcinoma.
View Article and Find Full Text PDFResearch progress and prospects of markers for liver cancer stem cells.
World J Gastroenterol
November 2015
Liver cancer is a common malignancy and surgery is the main treatment strategy. However, the prognosis is still poor because of high frequencies of postoperative recurrence and metastasis. In recent years, cancer stem cell (CSC) theory has evolved with the concept of stem cells, and has been applied to oncological research.
View Article and Find Full Text PDF